CVS Health Corporation $CVS Shares Sold by LSV Asset Management

LSV Asset Management lowered its stake in CVS Health Corporation (NYSE:CVS) by 3.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 4,619,061 shares of the pharmacy operator’s stock after selling 143,735 shares during the period. CVS Health accounts for approximately 0.8% of LSV Asset Management’s holdings, making the stock its 26th biggest holding. LSV Asset Management owned 0.36% of CVS Health worth $348,231,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. SOA Wealth Advisors LLC. increased its position in CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 131 shares during the period. Symmetry Partners LLC lifted its holdings in shares of CVS Health by 2.5% in the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares during the period. Harbor Capital Advisors Inc. raised its holdings in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 142 shares in the last quarter. HF Advisory Group LLC boosted its stake in shares of CVS Health by 2.9% during the 3rd quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock worth $393,000 after acquiring an additional 145 shares in the last quarter. Finally, United Asset Strategies Inc. lifted its stake in CVS Health by 1.8% during the third quarter. United Asset Strategies Inc. now owns 8,852 shares of the pharmacy operator’s stock valued at $667,000 after buying an additional 154 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

CVS has been the topic of several analyst reports. Morgan Stanley increased their price target on CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Bank of America reduced their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. TD Cowen boosted their target price on CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Piper Sandler restated an “overweight” rating and set a $101.00 target price (up from $99.00) on shares of CVS Health in a research report on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.82.

CVS Health Trading Up 1.6%

CVS opened at $76.88 on Thursday. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The company has a fifty day moving average of $78.55 and a 200-day moving average of $75.98. The stock has a market cap of $97.59 billion, a PE ratio of 55.71, a price-to-earnings-growth ratio of 0.70 and a beta of 0.50. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. CVS Health’s revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health’s dividend payout ratio is presently 700.00%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat and record revenue — CVS reported Q4 revenue of $105.7B (up 8.2%) and adjusted EPS that topped estimates, driven by Pharmacy and PBM strength; management cites progress on its turnaround. PR News Release
• Positive Sentiment: Analysts see multiple growth levers for 2026 — Sell‑side commentators highlight continued PBM, retail pharmacy margin recovery, and Aetna enrollment/efficiencies as upside drivers. Analysts See Multiple Growth Levers For CVS Health In 2026
• Positive Sentiment: Operational wins: cost‑based pharmacy transition & improved prior‑auth performance at Aetna — items that support margin recovery and execution credibility. PR News Release
• Neutral Sentiment: Sector context — Oscar Health and other insurers posted diverging 2025 results, keeping investor focus on insurer exposure and reimbursement trends rather than CVS‑specific fundamentals. CVS, Oscar Health report diverging 2025 results
• Neutral Sentiment: Mixed analyst commentary — some outlets and commentators (e.g., Jim Cramer) call CVS an attractive turnaround play, which supports sentiment but contrasts with caution around policy and guidance. Jim Cramer on CVS
• Negative Sentiment: Guidance shortfall vs. Street — management issued FY‑2026 EPS guidance (~$5.94–$6.14) below consensus estimates, prompting concern that near‑term earnings targets may be conservative versus sell‑side models. Zacks: Beats but Shares Slide
• Negative Sentiment: Medicare/MA rate concerns — investor worry about proposed Medicare rate changes and a “disappointing” 2027 Medicare Advantage rate notice from management weighed on sentiment and triggered earlier selling. Barron’s: Medicare Worries
• Negative Sentiment: Cash‑flow/guidance nuances — some reports flag lowered cash‑flow guidance or in‑line items that temper the upbeat revenue beat, which can pressure valuation near term. Investing.com: Cash Flow Guidance Lowered

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.